EA201692350A1 - Биомаркеры легочной гипертензии - Google Patents

Биомаркеры легочной гипертензии

Info

Publication number
EA201692350A1
EA201692350A1 EA201692350A EA201692350A EA201692350A1 EA 201692350 A1 EA201692350 A1 EA 201692350A1 EA 201692350 A EA201692350 A EA 201692350A EA 201692350 A EA201692350 A EA 201692350A EA 201692350 A1 EA201692350 A1 EA 201692350A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pulmonary hypertension
ccl21
biomarkers
modeling
biomarker
Prior art date
Application number
EA201692350A
Other languages
English (en)
Inventor
Марианна Роулэндс
Клеменс Анн Жанн Мари Тессье
Пол Эндрю Уиттейкер
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201692350A1 publication Critical patent/EA201692350A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Легочная гипертензия представляет собой прогрессирующее заболевание различной этиологии, которая ассоциируется с плохим прогнозом и приводит к правожелудочковой сердечной недостаточности. Имеющиеся в настоящее время данные указывают на важную роль иммунных клеток и воспалительных цитокинов в патогенезе и прогрессировании легочной гипертензии. Авторами настоящего изобретения был идентифицирован CCL21 как эффективный биомаркер легочной гипертензии, обладающий антиремоделирующей активностью. Было обнаружено, что CCL21 обладает высокой степенью чувствительности и специфичности, что позволяет дифференцировать пациентов с легочной гипертензией от соответствующего контроля. CCL21 активируется при легочной гипертензии и ингибируется после лечения антиремоделирующим агентом.
EA201692350A 2014-06-03 2015-05-29 Биомаркеры легочной гипертензии EA201692350A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14170962 2014-06-03
PCT/IB2015/054082 WO2015186037A1 (en) 2014-06-03 2015-05-29 Pulmonary hypertension biomarker

Publications (1)

Publication Number Publication Date
EA201692350A1 true EA201692350A1 (ru) 2017-04-28

Family

ID=50842165

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692350A EA201692350A1 (ru) 2014-06-03 2015-05-29 Биомаркеры легочной гипертензии

Country Status (11)

Country Link
US (3) US20170088897A1 (ru)
EP (1) EP3152327B1 (ru)
JP (1) JP6622722B2 (ru)
KR (1) KR20170013261A (ru)
CN (1) CN106460059B (ru)
AU (1) AU2015270185B2 (ru)
CA (1) CA2950527A1 (ru)
EA (1) EA201692350A1 (ru)
ES (1) ES2747381T3 (ru)
MX (1) MX2016015930A (ru)
WO (1) WO2015186037A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3537962A4 (en) * 2016-11-10 2019-11-27 Auburn University METHOD AND SYSTEM FOR ASSESSING A BLOOD VESSEL
CN106978485A (zh) * 2017-03-22 2017-07-25 首都医科大学 卵泡抑素样蛋白1对肺动脉高压的保护作用
WO2018213800A1 (en) * 2017-05-19 2018-11-22 The Board Of Trustees Of The Leland Stanford Junior University Enzastaurin and fragile histidine triad (fhit)-increasing agents for the treatment of pulmonary hypertension
CN107436333B (zh) * 2017-09-05 2019-12-20 中国医学科学院阜外医院 精胺作为标志物在制备肺动脉高压的诊断产品中的应用及医疗器械
WO2022202950A1 (ja) * 2021-03-25 2022-09-29 中外製薬株式会社 肺動脈性肺高血圧症患者の選定方法およびバイオマーカー
CN113493829B (zh) * 2021-09-09 2021-11-12 中日友好医院(中日友好临床医学研究所) 生物标志物在肺动脉高压诊疗中的应用
CN116148471B (zh) * 2022-11-01 2024-05-07 中南大学 肺动脉高压的生物标志物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US20060019272A1 (en) * 2004-05-03 2006-01-26 The Regents Of The University Of Colorado Diagnosis of disease and monitoring of therapy using gene expression analysis of peripheral blood cells
EP2120961A1 (en) * 2007-02-09 2009-11-25 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
KR101362951B1 (ko) * 2007-04-26 2014-02-28 동국대학교 산학협력단 기미 형성 예지방법 및 기미 형성 예지용 진단 키트
WO2009123730A1 (en) * 2008-04-02 2009-10-08 The Trustees Of The University Of Pennsylvania Methods for diagnosis and prognosis of pulmonary hypertension
CN101318932A (zh) * 2008-07-15 2008-12-10 东华大学 2′-羧基-5′-氟联苯衍生物、其制备及应用
WO2011080050A2 (en) * 2009-12-11 2011-07-07 Novartis Ag Binding molecules
NZ616308A (en) * 2011-04-08 2016-03-31 Biogen Ma Inc Biomarkers predictive of therapeutic responsiveness to ifnβ and uses thereof

Also Published As

Publication number Publication date
ES2747381T3 (es) 2020-03-10
JP6622722B2 (ja) 2019-12-18
CA2950527A1 (en) 2015-12-10
EP3152327B1 (en) 2019-06-26
MX2016015930A (es) 2017-04-11
US20170088897A1 (en) 2017-03-30
KR20170013261A (ko) 2017-02-06
AU2015270185B2 (en) 2018-07-05
US20200002768A1 (en) 2020-01-02
CN106460059A (zh) 2017-02-22
AU2015270185A1 (en) 2016-12-01
WO2015186037A1 (en) 2015-12-10
JP2017519498A (ja) 2017-07-20
CN106460059B (zh) 2021-07-13
EP3152327A1 (en) 2017-04-12
US20220389507A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
EA201692350A1 (ru) Биомаркеры легочной гипертензии
JP2012093361A5 (ru)
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
MX2016002165A (es) Beneficio de supervivencia en pacientes con tumores solidos con niveles elevados de proteina c reactiva.
MX2017003637A (es) Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
WO2015176066A3 (en) Lpa-associated protein and rna expression
EA201690456A1 (ru) Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов
EP3464638A4 (en) USE OF BIOMARKERS TO DETERMINE SENSITIVITY TO TREATMENT OF A DISEASE
EA201690534A1 (ru) Спироциклические соединения в качестве ингибиторов триптофангидроксилазы
EA201790211A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака
WO2015172085A3 (en) Biomarkers for response to pi3k inhibitors
EA201790549A1 (ru) Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли
EA201791424A1 (ru) Получение белка
WO2012112315A3 (en) Methods for diagnosis of kawasaki disease
WO2015048793A3 (en) Nucleic acid biomarker and use thereof
EA201692497A1 (ru) Биомаркеры ответа на ингибиторы ezh2
IN2012DN03817A (ru)
EA201690559A1 (ru) Способы определения ответа на терапию
NZ729773A (en) Biomarkers for disease progression in melanoma
EA201890649A1 (ru) Новые биомаркеры и способы лечения рака
HK1248810A1 (zh) 用於角膜擴張性疾病的診斷和預後的生物標記物
EA201791978A1 (ru) Биомаркеры преэклампсии
EA201790552A1 (ru) Применение элсиглутида для лечения мукозита желудочно-кишечного тракта, включая индуцированную химиотерапией диарею
MX2016006584A (es) Métodos y composiciones para tratar los depósitos de amiloide.
EA201501137A1 (ru) Биомаркеры генной экспрессии и их использование для диагностического и прогностического применения у пациентов, потенциально нуждающихся в лечении ингибитором hdac